A UCSF team found that Type 1 diabetes starts with "secretory senescence," a process whereby DNA damage causes beta cells to stop working properly.
Inovio spinout Geneos goes independent with a $10.5 million first-round financing for R&D in neoantigen-targeting cancer immunotherapies.
What if we could prevent opioid addiction before it starts? Reducing exposure to opioids after surgery through better non-opioid pain management options can…
Japanese pharma Daiichi Sankyo is looking to boost its research focus with a series of changes across its R&D.
The data show smoking reductions occurred within two days of treatment, sending the nanocap’s stock up as much as 90% in premarket trading.
The wipeout prompted Opiant to stop development of OPNT001 in the indication and double down on the rest of its pipeline.
Thermo Fisher halted DNA sequencer sales in western China after reports the genetic sequencers were used to power a state DNA surveillance program.
Propeller Health is partnering up with Orion to bring its digital inhaler platform to the Finnish drugmaker’s Easyhaler line of products.
Rutgers University scientists have made a surprising discovery that could lead to improved methods for diagnosing and treating human genetic diseases.
Rachelle Jacques, who most recently was a senior vice president at Alexion, takes over from Alvin Shih, M.D., who signed on at Enzyvant in November 2016.
Merck is making a $300 million move to acquire Immune Design, developers of a midphase immunotherapy for non-Hodgkin’s lymphoma.